Download the Prospectus
Pre Money Equity Valuation
$21,000,000
Min Raise
$7,000,000
Max Raise
$10,000,000
Estimated Close
2020-03-27
Issue Type
RTO or Recap
Lead Manager
Viriathus Capital
Type of Securities
Options, Shares
Date First Lodged
12/02/2020
Offer Costs $
$4,622,602
Market Cap Max
$31,000,000
Key Executives
Lou Panaccio (INEC), Glenn Tong (CEO and MD), Wei Jiang (NED), Jiayi Yu (ED), Weidong Chen (NED), Gregory Starr (ED)
Company Address
4503/19 Martin Place Sydney NSW 2000
Exchange
ASX
Chairman's Letter

Dear Investor,
On behalf of the Board of Directors it is with great pleasure that I invite you to become a shareholder
of Azure Health.
The business of Azure Health is the development, production, marketing and sale of health and
wellbeing products including the development and commercialisation of platforms for the noninvasive delivery of tocotrienols (a form of Vitamin E) for both nutraceutical and pharmaceutical
applications. The intellectual property assets and business model of Azure Health are as yet
unproven, and an investment in Azure Health should be regarded as speculative. Accordingly, there
can be no guarantee of the payment of any dividends.
Azure Health is led by a team with significant experience in the healthcare industry. I believe the
Directors and Management of Azure Health have the capabilities to successfully support the
development and growth of Azure Health to deliver real value to the community and to
Shareholders.
Completion of the Proposed Transactions (the Invictus acquisition and the Offer) is subject to a
number of conditions precedent being satisfied or waived. These include Shareholder approval, the
completion the Offer under this Prospectus and the Company re-complying with Chapters 1 and 2
of the ASX Listing Rules. The Company’s Shares will remain suspended from the ASX until the Company
has re-complied with Chapters 1 and 2.
This Prospectus is being issued to assist the Company to re-comply with the ASX Listing Rules and also
to raise sufficient funds to complete the Proposed Transactions and provide working capital. Under
this Prospectus, the Company proposes to raise up to $10,000,000 via the issue of up to 50,000,000
Shares (post Consolidation) at an Offer Price of $0.20 per Share.
This Prospectus contains detailed information about Azure Health, the Offer and the key risks of an
investment of this nature. The key risks associated with an investment in the Company are set out in
detail in Section 5.
I encourage you to read the Prospectus in full and to carefully consider the Offer, including the risks
of investing in Azure Health. Please consult your financial advisor before making an investment
decision.
On behalf of my fellow Directors, I invite you to subscribe for Shares in Azure Health and look forward
to working to deliver its anticipated success.
Yours sincerely
Lou Panaccio
Chairman